This research identifies a Paneth-like cell transition as a primary driver of non-genetic resistance to combined KRAS and EGFR inhibition in colorectal cancer (CRC). By utilizing genetically engineered mouse models and patient-derived organoids, the authors demonstrate that CRC cells adopt a secretory lineage state to evade therapeutic pressure and reactivate MAPK signaling. The study reveals that the SMAD1-FGFR3 signaling axis orchestrates this cellular plasticity and lineage switch. Importantly, the researchers found that pharmacological or genetic inhibition of FGFR3 effectively blocks this transition and restores drug sensitivity. These findings suggest that triple combination therapy—targeting KRAS, EGFR, and FGFR3—could prevent treatment relapse in patients with KRAS-mutant CRC. Evidence from clinical biopsies confirms that this Paneth-like enrichment is a conserved survival strategy in human patients undergoing targeted therapy.

References:

• Zhang Y, Chen J, She Y, et al. Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer[J]. Cancer Cell, 2025.